California Pharmacy Technician Bus. & Prof. Code § 4202 Attorney Fee Petition Mechanics: Board of Pharmacy License Verification and PTCB CPhT Verification as Dual Institutional Anchors (the Only § 4202 Pharmacy Technician Page — Distinct From Pharmacist § 4050, Pharmacy Intern § 4208, and Medication Aide), PTCB Certification Examination Standards and ASHP Technician Education Standards as Private Advisory Standards (Pure Ketchum), CLRA § 1780 Mandatory Attorney Fees for Three-Track Harm: Methotrexate Weekly-as-Daily Dispensing Error §145K / USP <797> Sterile Compounding Breach Bacteremia §95K / Controlled Substance Diversion Schedule II §45K

Statutory Framework: Bus. & Prof. Code § 4202 — California Pharmacy Technician License Requirements, Scope of Supervised Practice, and CLRA § 1780 Mandatory Attorney Fees for Unlicensed Pharmacy Technician Practice

California Business and Professions Code § 4202 establishes the foundational prohibition against unlicensed pharmacy technician practice in California: no person may perform the functions of a pharmacy technician — including prescription label generation, pill counting and verification, drug-drug interaction screening, prescription transcription from written or telephoned orders, controlled substance inventory management, and sterile compounding support tasks — in any California licensed pharmacy, hospital pharmacy, clinic pharmacy, or compounding facility, without first obtaining a current pharmacy technician license issued by the California State Board of Pharmacy. The CBP pharmacy technician license is issued only after the applicant completes one of two authorized licensing pathways: (1) passage of the PTCB CPhT (Certified Pharmacy Technician) national examination administered by the Pharmacy Technician Certification Board — a four-domain examination covering Medications (50%), Federal Requirements (12.5%), Patient Safety and Quality Assurance (26.25%), and Order Entry and Processing (11.25%); or (2) completion of an ASHP/ACPE-accredited pharmacy technician education and training program meeting the ASHP Standards for competency in dispensing functions, drug interaction screening, and sterile compounding. Once licensed, the pharmacy technician must renew every two years and complete 20 hours of continuing pharmacy education per renewal cycle, including mandatory hours in medication error prevention and pharmacy law.

The critical distinction between the § 4202 Pharmacy Technician license and the § 4050 Registered Pharmacist (RPh) license defines the legal boundaries of the technician's supervised scope of practice: a Pharmacy Technician performs dispensing support tasks under the supervision and direction of a licensed pharmacist but has no authority to independently verify dispensing accuracy, provide patient counseling, make clinical therapeutic decisions regarding drug selection or substitution, interpret clinical laboratory values bearing on drug therapy, or perform collaborative drug therapy management (CDTM) under standardized procedures agreements. Every prescription dispensed through pharmacy technician task performance must receive a final pharmacist verification check before the dispensed product is delivered to the patient — a verification step that an unlicensed individual performing pharmacy technician functions without a § 4202 license either bypasses entirely or performs without the requisite training and without the supervising pharmacist's awareness of the unlicensed status. This pharmacist verification requirement is the critical safety checkpoint that the unlicensed technician's presence in the dispensing workflow corrupts, creating the predicate conditions for the methotrexate dispensing label error, the sterile compounding breach, and the controlled substance diversion harm tracks in § 4202 CLRA § 1780 claims.

The CLRA civil remedy in § 4202 unlicensed pharmacy technician cases arises because pharmacy dispensing services — including outpatient prescription dispensing, hospital inpatient medication preparation, and sterile compounding for immunocompromised oncology patients — are consumer services purchased for personal, family, and health use within the meaning of Civil Code § 1761(b). Any pharmacy, clinic, or healthcare institution that holds itself out to the public as providing licensed pharmaceutical services implicitly represents that its dispensing personnel hold current California Board of Pharmacy licensure, including current § 4202 pharmacy technician licenses for all technician-scope personnel. This implied representation constitutes a misrepresentation of service provider qualifications under Civil Code § 1770(a)(14) when the dispensing or compounding work was performed by an unlicensed individual. Civil Code § 1780(e) mandates: "the court shall award court costs and attorney's fees to a prevailing plaintiff in litigation filed pursuant to this section" — eliminating judicial discretion and establishing CLRA § 1780 as a pure mandatory fee statute for unlicensed pharmacy technician practice claims. UCL § 17200 provides a parallel per se unlawful business practice theory, since operating a pharmacy with unlicensed dispensing personnel is an unlawful business act regardless of whether specific patient harm resulted from any individual transaction. CCP § 1021.5 independently supports private attorney general fees for CBP licensing enforcement, given the substantial public interest in ensuring that California patients receive prescription medications dispensed by personnel who meet the CBP's documented competency standards for high-alert medication handling, drug interaction screening, and sterile compounding aseptic technique.

Two Private Standards — Pure Ketchum: PTCB Pharmacy Technician Certification Examination Standards and ASHP Standards for Pharmacy Technician Education and Training Programs

PTCB PHARMACY TECHNICIAN CERTIFICATION EXAMINATION STANDARDS — THE ONLY PAGE IN THE FEE-PETITION-MECHANICS SERIES WITH A PTCB CERTIFICATION STANDARDS ADVISORY: the Pharmacy Technician Certification Board (PTCB) is a private nonprofit credentialing organization founded in 1995 as a joint venture of the American Pharmacists Association (APhA), the American Society of Health-System Pharmacists (ASHP), the National Association of Boards of Pharmacy (NABP), and the National Community Pharmacists Association (NARD). The PTCB CPhT examination is the national pharmacy technician certification credential recognized by the California State Board of Pharmacy as one of two pathways to § 4202 licensure. The PTCB examination is organized into four content domains that define the professional competency baseline for licensed pharmacy technicians: (1) Medications (50% of examination content) — drug name recognition including brand and generic names and common abbreviations; look-alike/sound-alike (LASA) drug pair identification and error-prevention protocols; drug interactions and therapeutic equivalence; and the ISMP (Institute for Safe Medication Practices) high-alert medication list, which includes anticoagulants (warfarin, heparin, low-molecular-weight heparins), concentrated electrolytes (potassium chloride injection 2 mEq/mL, hypertonic sodium chloride), opioids (oxycodone, hydrocodone, fentanyl, morphine), insulin (all types), and methotrexate (specifically the weekly-dosing requirement for oral methotrexate in inflammatory arthritis indications, which is a well-documented ISMP high-alert medication error pattern); (2) Federal Requirements (12.5%) — DEA controlled substance Schedules II–V dispensing requirements, pharmacist verification requirements before dispensing, DEA Form 222 for Schedule II transfers, CSOS electronic ordering, and controlled substance inventory reconciliation; (3) Patient Safety and Quality Assurance (26.25%) — error prevention strategies, ISMP high-alert medication identification and counseling flag protocols, prescription label accuracy requirements, beyond-use dating, error reporting through MedWatch and ISMP's National Medication Errors Reporting Program (ISMP MERP), and the five rights of medication administration as applied to pharmacy dispensing (right patient, right drug, right dose, right route, right time); (4) Order Entry and Processing (11.25%) — prescription transcription accuracy from written, telephoned, and electronic orders; label generation and verification; and pharmacy computer system data entry quality assurance protocols.

PURE KETCHUM: the PTCB Pharmacy Technician Certification Examination Standards are the credentialing standards of a private nonprofit organization — not a California statute, regulation, or enforceable standard of care imposing civil liability. They create no fee-shifting obligation against an unlicensed pharmacy technician defendant and provide no independent basis for attorney fee recovery in California superior court. The PTCB Certification Standards are analyzed in the § 4202 CLRA § 1780 fee petition as pure Ketchum advisory material — to establish the professional competency benchmarks the unlicensed technician failed to meet, to document the specific PTCB Medications domain high-alert medication protocol deviations (particularly the ISMP methotrexate weekly-dosing flag that the unlicensed technician failed to recognize and escalate for pharmacist review), and to support the Ketchum multiplier briefing by demonstrating the specialized pharmaceutical knowledge required to prosecute pharmacy technician competency deviation claims. The entire CLRA § 1780 lodestar arising from PTCB Standards analysis is pure Ketchum, eligible for the full Ketchum contingency multiplier without any Dague constraint.

ASHP STANDARDS FOR PHARMACY TECHNICIAN EDUCATION AND TRAINING PROGRAMS — THE ONLY PAGE IN THE FEE-PETITION-MECHANICS SERIES WITH AN ASHP PHARMACY TECHNICIAN EDUCATION STANDARDS ADVISORY: the American Society of Health-System Pharmacists (ASHP) is a private nonprofit professional pharmacy organization founded in 1942 that serves as the national accrediting body for pharmacy technician education and training programs through its collaboration with the Accreditation Council for Pharmacy Education (ACPE). The ASHP Standards for Pharmacy Technician Education and Training Programs establish the minimum competency requirements for graduates of ASHP/ACPE-accredited programs, which constitute one of the two California-recognized pathways to § 4202 licensure. The ASHP Standards specify competency in two domains directly relevant to the three-track harm in § 4202 CLRA § 1780 claims: (1) Dispensing competency — requiring graduates to demonstrate mastery of prescription label accuracy verification (including verification of patient name, prescriber name, drug name and strength, directions for use, quantity dispensed, beyond-use date, and appropriate auxiliary labels such as the ISMP high-alert drug cautionary labels); pill count confirmation protocols; drug-drug interaction screening using pharmacy computer systems; and LASA drug pair recognition protocols, including specific recognition of the methotrexate weekly-dosing requirement for rheumatoid arthritis and psoriasis indications versus the daily-dosing requirement for oncologic indications; (2) Sterile compounding competency — requiring graduates to demonstrate mastery of USP Chapter <797> aseptic technique including: use of an ISO Class 5 primary engineering control (PEC) — specifically, a laminar airflow workbench (LAFW) for conventional sterile preparations and a biological safety cabinet (BSC) for hazardous drug preparations — for all compounded sterile preparations; ISO Class 7 buffer room requirements for the immediate compounding environment; complete garbing protocol (hand hygiene with antimicrobial soap, sterile gloves, gown with closed cuffs, mask, hair cover, and shoe covers) before entering the ISO Class 5 PEC; beyond-use dating assignment for compounded sterile preparations based on sterility risk level (low-risk CSPs: 48-hour room temperature/14-day refrigerated/45-day frozen beyond-use dates); and environmental monitoring sampling (viable air sampling, surface sampling, and gloved fingertip sampling). ASHP explicitly identifies that pharmacy technicians without proper sterile compounding training performing sterile preparation tasks outside an ISO Class 5 PEC — on an open bench counter without a laminar airflow workbench — constitutes a patient safety violation under the ASHP Standards and the USP Chapter <797> framework.

PURE KETCHUM: the ASHP Standards for Pharmacy Technician Education and Training Programs are the accreditation standards of a private professional organization — not a California statute or enforceable regulatory standard creating civil liability. They create no fee-shifting obligation and provide no independent basis for attorney fee recovery in California superior court. The ASHP Standards are analyzed in the § 4202 CLRA § 1780 fee petition as pure Ketchum advisory material — to establish the sterile compounding competency baseline the unlicensed technician demonstrably lacked when performing vancomycin IV admixture preparation on an open bench counter without an ISO Class 5 LAFW, and to support the Ketchum multiplier briefing by demonstrating the specialized USP Chapter <797> aseptic technique knowledge required to prosecute sterile compounding breach claims. TWO PRIVATE STANDARDS ON ONE PAGE: the PTCB Certification Examination Standards and the ASHP Technician Education Standards each address distinct competency domains — the PTCB Standards define the knowledge benchmarks tested at entry-level certification (Medications, Federal Requirements, Patient Safety, and Order Entry), while the ASHP Standards define the training program competency outcomes required by the accreditation framework (dispensing workflow and sterile compounding aseptic technique) — together establishing a comprehensive professional competency baseline against which the unlicensed defendant's multiple concurrent competency failures can be documented and briefed in the fee petition.

Distinct From: Pharmacist (§ 4050), Pharmacy Intern (§ 4208), and Medication Aide

• Distinct from California Pharmacist — Bus. & Prof. Code § 4050 (licensed pharmacist who independently verifies prescriptions, provides patient counseling, makes clinical therapeutic decisions, interprets clinical laboratory values, and performs CDTM under standardized procedures agreements): the § 4050 Registered Pharmacist is the licensed professional who independently oversees and verifies all dispensing activity in a California pharmacy, providing the final pharmacist-level verification check that validates every prescription before dispensing to the patient; the pharmacist independently counsels patients on new and refill prescriptions, documents medication therapy management (MTM) encounters, identifies and resolves drug therapy problems, makes therapeutic substitution decisions, manages collaborative drug therapy management (CDTM) protocols for anticoagulation, lipid management, diabetes, and HIV therapy, and interprets clinical laboratory values bearing on drug therapy optimization; the § 4202 Pharmacy Technician performs tasks under pharmacist supervision and direction but cannot independently verify dispensing accuracy (every technician-dispensed prescription requires pharmacist final verification), cannot provide patient counseling, cannot make clinical decisions about drug selection, substitution, or dosing, and cannot independently manage CDTM protocols; the § 4202 CLRA § 1780 unlicensed pharmacy technician claim is categorically distinct from the § 4060 unlicensed pharmacy practice claim — which covers unlicensed Registered Pharmacists performing full pharmacist-scope services — because the § 4202 claim targets the supervised-scope dispensing support function that underlies the pharmacist verification checkpoint, not the independent clinical judgment function that defines pharmacist practice; THE § 4060 UNLICENSED PHARMACY PRACTICE PAGE USES THE CBP BREEZE LICENSE VERIFICATION MODULE AS ITS SECONDARY ANCHOR — AN ENTIRELY DISTINCT ANCHOR FROM THE PTCB.ORG CPHT VERIFICATION USED AS THE SECONDARY ANCHOR ON THIS PAGE
• Distinct from California Pharmacy Intern — Bus. & Prof. Code § 4208 (licensed pharmacy student or graduate performing pharmacist-scope duties under direct pharmacist supervision as part of the education and licensing process, with a distinct intern license bearing an INT prefix in the CBP license verification system): the § 4208 Pharmacy Intern is a licensed pharmacy student or PharmD graduate performing pharmacist-scope activities — including patient counseling, drug therapy assessment, and prescription verification under direct pharmacist supervision — as part of the formal education and licensing process toward a § 4050 Registered Pharmacist license; the Pharmacy Intern's scope is defined by the activities authorized under the pharmacist supervisor's direct oversight within the intern's pharmacy education program, not by the technician's supervised dispensing support functions; the Pharmacy Intern license (INT prefix) is issued by the CBP separately from both the Pharmacy Technician license (TCH prefix) and the Registered Pharmacist license (RPh prefix) — an individual holding only an INT license may not independently perform pharmacy technician functions without pharmacist supervision, and an individual holding only a TCH license may not perform pharmacist-scope services including patient counseling or independent prescription verification; the unlicensed defendant in a § 4202 CLRA § 1780 claim holds neither a TCH-prefix pharmacy technician license nor any other current CBP authorization to perform pharmacy technician tasks
• Distinct from Medication Aide (no separate California DCA pharmacy license — hospital-based medication administration by CNAs and nursing assistants regulated under nursing board scope, not pharmacy board scope): medication aides — certified nursing assistants (CNAs) or nursing assistants who have completed additional training in medication administration under the supervision of a licensed nurse — operate under the California Board of Registered Nursing's delegation framework and nursing scope of practice, not the California State Board of Pharmacy's licensing framework; medication aide functions are limited to administering pre-prepared, pre-packaged unit-dose medications to specific identified patients in licensed skilled nursing facilities and other specified healthcare settings, under a licensed nurse's supervision and direction; medication aides do not perform pharmacy technician functions (prescription label generation, pill counting, drug-drug interaction screening, prescription transcription, sterile compounding) and are not subject to § 4202 CBP licensing requirements; the § 4202 CLRA § 1780 unlicensed pharmacy technician claim applies to individuals performing pharmacy-scope dispensing, compounding, and controlled substance management functions within a pharmacy or compounding facility setting under the CBP's regulatory jurisdiction, not to nursing-supervised medication administration in a patient care setting under the nursing board's jurisdiction

Three-Track Harm: Methotrexate Weekly-as-Daily Dispensing Label Error ($145,000) / USP <797> Sterile Compounding Breach Bacteremia ($95,000) / Controlled Substance Diversion Schedule II ($45,000)

Track 1 — METHOTREXATE DISPENSING LABEL ERROR: WEEKLY METHOTREXATE 15 MG (RHEUMATOID ARTHRITIS ONCE-WEEKLY DOSING) — UNLICENSED PHARMACY TECHNICIAN GENERATED LABEL READING "TAKE ONE TABLET DAILY" INSTEAD OF "TAKE ONE TABLET ONCE WEEKLY ON [DAY]" — PHARMACIST VERIFICATION BYPASSED — PATIENT TOOK 15 MG DAILY FOR 7 DAYS — 7× THERAPEUTIC DOSE ACCUMULATION — METHOTREXATE TOXICITY: PANCYTOPENIA (ANC 0.3, PLATELETS 18K), ORAL MUCOSITIS GRADE 3, HEPATOTOXICITY (ALT 485 U/L) — HOSPITALIZATION 12 DAYS — LEUCOVORIN RESCUE — FILGRASTIM G-CSF — $145,000: oral methotrexate in the 7.5 mg to 25 mg dose range is prescribed once weekly for rheumatoid arthritis, psoriasis, and psoriatic arthritis — a dosing schedule that is one of the most well-documented ISMP high-alert medication error patterns in outpatient pharmacy practice, because the weekly dosing interval is counterintuitive to patients who are accustomed to daily medications and because the label's "daily" versus "once weekly on [day]" language distinction is easily corrupted in prescription transcription. The PTCB Pharmacy Technician Certification Examination Standards specifically identify methotrexate as an ISMP high-alert medication requiring recognition of the LASA error risk between once-weekly arthritis dosing and daily oncologic dosing, and require that pharmacy technicians recognize the weekly-dosing flag and escalate any ambiguity in the prescription transcription to the supervising pharmacist before generating the dispensing label. The unlicensed technician in this scenario — operating without a CBP § 4202 license and without the PTCB examination training that would have embedded the ISMP methotrexate weekly-dosing flag — transcribed the prescriber's written "once weekly" instruction as "daily" in the pharmacy computer system, generating a dispensing label that instructed the patient to take one tablet daily. The supervising pharmacist's verification step — the checkpoint designed to catch exactly this category of LASA transcription error — was bypassed because the unlicensed technician was performing the dispensing task without disclosing the unlicensed status to the pharmacy's workflow management. The patient took 15 mg daily for seven days, accumulating 105 mg of methotrexate — a 7× therapeutic dose — producing classic severe methotrexate toxicity: pancytopenia with absolute neutrophil count of 0.3 ×10³/µL (profound neutropenia) and platelet count of 18,000/µL (hemorrhagic thrombocytopenia); grade 3 oral mucositis with inability to eat; and hepatotoxicity with ALT elevation to 485 U/L (approximately 12× the upper limit of normal). Hospitalization for 12 days required leucovorin (folinic acid) rescue therapy to reverse the methotrexate toxicity, filgrastim (G-CSF) to stimulate neutrophil recovery, broad-spectrum antibiotic coverage for febrile neutropenia prophylaxis during the neutropenic nadir, platelet transfusion for the hemorrhagic thrombocytopenia, and intensive supportive care for the oral mucositis. Total damages: $145,000.

Track 2 — USP CHAPTER <797> STERILE COMPOUNDING BREACH: VANCOMYCIN 1G IV ADMIXTURE COMPOUNDED BY UNLICENSED PHARMACY TECHNICIAN WORKING OUTSIDE ISO CLASS 5 LAFW (COMPOUNDING PERFORMED ON OPEN BENCH COUNTER WITHOUT PRIMARY ENGINEERING CONTROL) — CONTAMINATION WITH BURKHOLDERIA CEPACIA COMPLEX — 3 IMMUNOCOMPROMISED PATIENTS (ONCOLOGY UNIT) DEVELOPED BLOODSTREAM INFECTIONS — SEPSIS — ICU ADMISSION — PROLONGED ANTIBIOTIC THERAPY — $95,000 PER PATIENT (LEADING PLAINTIFF): vancomycin 1g in 250 mL normal saline IV admixtures are compounded sterile preparations (CSPs) requiring preparation inside an ISO Class 5 primary engineering control — a laminar airflow workbench (LAFW) in a pharmacy-grade cleanroom environment meeting USP Chapter <797> requirements — because IV admixtures bypass the body's natural infection defenses and any microbial contamination introduced during compounding is delivered directly into the bloodstream. The ASHP Standards for Pharmacy Technician Education and Training Programs, which define the sterile compounding competency requirements for the § 4202 licensing pathway, explicitly require that pharmacy technicians performing sterile compounding demonstrate mastery of USP Chapter <797> aseptic technique including mandatory use of an ISO Class 5 PEC (LAFW or BSC) for all CSP preparation. The unlicensed pharmacy technician in this scenario — without a CBP § 4202 license and without the ASHP-accredited training that would have instilled USP Chapter <797> aseptic technique competency — prepared vancomycin IV admixtures on an open bench counter in the pharmacy's general dispensing area, outside any ISO Class 5 LAFW, without the full garbing protocol (sterile gloves, gown, mask, hair cover, shoe covers) required for ISO Class 5 PEC work. The open-bench compounding introduced Burkholderia cepacia complex, an opportunistic pathogen notorious for contaminating pharmaceutical products and particularly dangerous in immunocompromised patients. Three immunocompromised oncology unit patients who received the contaminated vancomycin admixtures developed Burkholderia cepacia complex bloodstream infections, with sepsis requiring ICU admission and prolonged courses of trimethoprim-sulfamethoxazole and meropenem therapy for B. cepacia bacteremia. The leading plaintiff's damages: $95,000.

Track 3 — CONTROLLED SUBSTANCE DIVERSION: OXYCODONE-ACETAMINOPHEN 10/325 TABLETS — UNLICENSED INDIVIDUAL PERFORMING PHARMACY TECHNICIAN DUTIES WITHOUT VALID § 4202 LICENSE SUBSTITUTED DISPENSED OXYCODONE TABLETS WITH PLACEBO CALCIUM CARBONATE TABLETS — POST-SURGICAL PATIENTS AT ORTHOPEDIC CLINIC RECEIVED NO EFFECTIVE ANALGESIA — 6 PATIENTS PRESENTED TO EMERGENCY DEPARTMENT WITH UNCONTROLLED PAIN — SURGICAL WOUND COMPLICATIONS IN 2 PATIENTS — $45,000 (LEADING PLAINTIFF): controlled substance diversion by pharmacy personnel — the theft of dispensed Schedule II opioids for personal use or resale, replaced with lookalike placebo tablets to conceal the theft — is a patient safety event pattern that the CBP § 4202 licensing framework is designed to prevent through the controlled substance inventory reconciliation competency requirements in the PTCB Federal Requirements domain. Licensed pharmacy technicians undergo CBP background check screening as part of the § 4202 license application process, and the PTCB Federal Requirements domain specifically covers DEA Schedule II controlled substance inventory management, biennial physical inventory requirements, DEA Form 41 destruction protocols, and reconciliation of dispensing records against perpetual inventory to detect diversion. The unlicensed individual performing pharmacy technician duties in this scenario — without a CBP § 4202 license and without the controlled substance inventory management training embedded in the PTCB Federal Requirements domain — systematically substituted dispensed oxycodone-acetaminophen 10/325 tablets with calcium carbonate tablets in dispensing vials for post-surgical orthopedic clinic patients. Six patients who received the adulterated dispensed opioid vials — expecting effective Schedule II analgesic coverage for post-operative orthopedic pain — presented to the emergency department with uncontrolled pain when the calcium carbonate placebo provided no analgesia for post-surgical pain. Two patients developed surgical wound complications attributable to inadequate pain control and resulting impaired mobility and wound healing during the immediate post-operative period. The leading plaintiff's damages from inadequate post-operative analgesia, emergency department visits, and wound care complications: $45,000.

Primary Welch Anchor: California Board of Pharmacy License Verification at search.dca.ca.gov

The California Board of Pharmacy license verification at search.dca.ca.gov (the DCA's BreEZe public license verification portal) is the primary Welch anchor for the CLRA § 1780 attorney fee petition lodestar in Bus. & Prof. Code § 4202 unlicensed pharmacy technician cases. When the attorney searches the CBP license database at search.dca.ca.gov for the defendant's name and confirms either the absence of any TCH-prefix pharmacy technician license or the presence of an Expired, Delinquent, Suspended, or Revoked TCH license as of the dates of the unlicensed dispensing, compounding, or controlled substance management activities, the search date establishes the primary Welch temporal anchor for the CLRA § 1780 fee petition. The CBP BreEZe module records for each licensed pharmacy technician: the TCH-prefix license number; the licensee's full legal name; the license type (Pharmacy Technician); the license issue date; the license expiration date (biennial renewal required); the current license status (Clear, Expired, Delinquent, Suspended, Revoked, or Probation); and any CBP disciplinary history including citations for unlicensed practice, accusations, and consent agreements. The attorney's contemporaneous documentation of the CBP license search result — including the search date, the specific database queried (search.dca.ca.gov, CBP module), the defendant's name as searched, the search result (no license found / license status confirmed as [Expired/Revoked/etc.] as of [date]), and a screenshot or printed search result preserved in the client file — constitutes the primary Welch anchor establishing the fee petition start date.

In most § 4202 unlicensed pharmacy technician matters, the CBP license verification search is performed early in the pre-complaint advisory phase, after the plaintiff attorney receives the initial client contact describing the dispensing error, sterile compounding failure, or controlled substance diversion event. The attorney will typically obtain: the name or names of the pharmacy technician personnel who performed the specific dispensing, compounding, or controlled substance management functions at issue; the pharmacy's name and CBP pharmacy license number (PHY-prefix) to confirm the pharmacy entity's licensing status; the dates of the dispensing, compounding, or controlled substance management activities at issue; and, in cases involving a PTCB CPhT credential claim by the defendant technician, the PTCB CPhT certification number to be cross-referenced at ptcb.org. The CBP license database search at search.dca.ca.gov simultaneously establishes: (a) the primary Welch anchor date; (b) the per se violation of § 4202 (unlicensed pharmacy technician practice); (c) the predicate credential misrepresentation triggering CLRA § 1780 mandatory attorney fees (the defendant's implied or express representation of CBP § 4202 licensure in the pharmacy dispensing workflow); and (d) the factual predicate for the UCL § 17200 per se unlawful business practice claim (operating a pharmacy dispensing workflow with unlicensed technician personnel is unlawful under § 4202 regardless of whether any specific transaction caused patient harm).

The CBP BreEZe module used for § 4202 pharmacy technician license verification (TCH-prefix records) is the same BreEZe platform used for CBP § 4050 pharmacist license verification (RPh-prefix records) and CBP § 4208 pharmacy intern license verification (INT-prefix records), but the three license types are maintained as separate credential categories within the CBP BreEZe module, each with distinct license number prefixes, distinct renewal cycles, and distinct scope-of-practice authorizations. An attorney searching for a pharmacy technician should specifically filter the CBP BreEZe search by license type "Pharmacy Technician (TCH)" to avoid any confusion with RPh or INT license records. The CBP's license verification at search.dca.ca.gov is the definitive public record of § 4202 authorization — a PTCB CPhT national certification certificate, an employer identification badge, or a pharmacy school enrollment record does not substitute for a current CBP § 4202 TCH-prefix license in the BreEZe database.

Secondary Institutional Anchor: PTCB CPhT Certification Verification at ptcb.org — The Only ptcb.org Anchor in the Series

The PTCB CPhT (Certified Pharmacy Technician) certification verification at ptcb.org is the secondary institutional anchor in Bus. & Prof. Code § 4202 unlicensed pharmacy technician fee petition cases — THE ONLY SECONDARY INSTITUTIONAL ANCHOR IN THE ENTIRE FEE-PETITION-MECHANICS SERIES TIED SPECIFICALLY TO PTCB.ORG AND THE PTCB CPhT NATIONAL CREDENTIALING PROGRAM. The Pharmacy Technician Certification Board maintains a public certification verification system at ptcb.org that allows attorneys, employers, and the public to verify whether a specific individual holds a current, active PTCB CPhT credential — the national pharmacy technician certification that, combined with the CBP license application, constitutes one of the two authorized pathways to § 4202 licensure in California. For each CPhT credential holder, the PTCB verification system records: the CPhT certification number; the certified individual's full legal name; the certification status (Active, Expired, Revoked, or Suspended); the certification effective date; the certification expiration date (recertification required every two years with 20 hours of pharmacy technician continuing education); and any PTCB disciplinary actions against the certification for examination misconduct or professional conduct violations.

The PTCB CPhT certification verification at ptcb.org functions as the secondary Welch anchor in § 4202 fee petition matters for a distinct and complementary reason: many unlicensed pharmacy technician defendants will claim, either informally or as a formal defense, that they hold a current PTCB CPhT national certification and therefore believed themselves to be qualified to perform pharmacy technician functions in California. Searching ptcb.org to verify the defendant's PTCB CPhT status — and cross-referencing the ptcb.org verification result against the CBP BreEZe search result — is an essential step that either (a) confirms the defendant holds neither a California CBP § 4202 license nor a PTCB CPhT certification (establishing the complete absence of both state licensure and national credentialing), or (b) confirms the defendant holds a PTCB CPhT national certification but lacks the California CBP § 4202 state license (establishing the critical point that PTCB CPhT national certification is not a substitute for California § 4202 state licensure, and that the defendant cannot avail themselves of a good-faith reliance defense based on holding a PTCB credential without a California CBP license). In either scenario, the ptcb.org search date — documented with contemporaneous time records and screenshot preservation — establishes the secondary Welch anchor and is the event from which all subsequent pre-complaint advisory tasks (PTCB Certification Standards high-alert medication protocol deviation analysis, ASHP Standards sterile compounding deviation analysis, expert consultation, and advisory calls on the three harm tracks) are organized in the CLRA § 1780 fee petition lodestar narrative.

The ptcb.org secondary anchor is entirely distinct from every other secondary institutional anchor used in the fee-petition-mechanics series: it is not a government agency database (unlike the CBP BreEZe, the BRN BreEZe, the DRE BreEZe, or the DCA search portal used for other professional licensing board pages); it is not an accreditation or certification database maintained by a state agency (unlike the CSLB contractor license verification, the CalBar attorney verification, or the BRE appraiser verification); and it is the only secondary anchor in the series hosted on a private nonprofit credentialing organization's own website (“ptcb.org”) rather than on a government or quasi-governmental portal. This distinction reflects the unique dual-licensing structure of California pharmacy technician regulation, where the California CBP state license and the national PTCB CPhT certification occupy separate but overlapping roles in establishing practitioner competency: the CBP license is the state authorization to practice; the PTCB CPhT certification is the national competency credential that one licensing pathway requires; and verifying both — through search.dca.ca.gov for the CBP license (primary anchor) and ptcb.org for the PTCB certification (secondary anchor) — provides the most complete documentation of the defendant's credential status for the § 4202 CLRA § 1780 fee petition.

Billing Gap 1 — Board of Pharmacy License Verification, PTCB CPhT Verification, ASHP Sterile Compounding Standards Deviation Analysis, and Three Advisory Calls for Three Harm Tracks (5.25 hrs/yr = $1,575–$2,625)

The first billing gap arises in the pre-complaint advisory phase — from initial patient contact through complaint filing — during which the attorney searches the CBP license verification database at search.dca.ca.gov, cross-references the PTCB CPhT verification at ptcb.org, analyzes the PTCB Certification Standards high-alert medication protocol deviations and the ASHP Standards USP Chapter <797> sterile compounding deviations applicable to the specific harm tracks at issue, and conducts advisory calls with the patient on each of the three harm tracks (methotrexate dispensing label error, sterile compounding breach, and controlled substance diversion).

• Searching the CBP license verification database at search.dca.ca.gov (primary Welch anchor) and cross-referencing the PTCB CPhT certification verification at ptcb.org (secondary anchor) to confirm the defendant's unlicensed and/or uncertified status: the attorney searches the CBP BreEZe module at search.dca.ca.gov for the defendant pharmacy technician's full name, filtering by license type "Pharmacy Technician (TCH)," to confirm the absence of a current Clear TCH-prefix license or the presence of an Expired, Delinquent, Suspended, or Revoked TCH license as of the relevant dates; the attorney also searches the pharmacy entity's PHY-prefix license status to determine whether the pharmacy itself is a compliant CBP-licensed entity; concurrently, the attorney searches ptcb.org to verify the defendant's PTCB CPhT certification status (Active, Expired, Revoked, or not found), documenting the relationship between the defendant's national certification status and the absence of California state licensure; both search results are preserved with contemporaneous time records documenting the search dates, the specific databases searched, the search terms used, and the results obtained, establishing both the primary and secondary Welch anchors for the CLRA § 1780 fee petition lodestar.
• Analyzing the PTCB Pharmacy Technician Certification Examination Standards (PURE KETCHUM) for high-alert medication protocol deviations applicable to the methotrexate weekly-as-daily dispensing label error — specifically, the ISMP high-alert medication list, the LASA drug pair recognition protocols, and the mandatory pharmacist escalation requirement for ambiguous weekly-dosing prescriptions: the attorney reviews the PTCB Medications domain content specifications identifying methotrexate as an ISMP high-alert medication requiring specific LASA recognition protocols for weekly-dosing rheumatoid arthritis prescriptions versus daily-dosing oncologic prescriptions; the attorney documents the specific PTCB competency benchmark the unlicensed technician failed to meet — recognizing the once-weekly dosing instruction as a PTCB-identified high-alert medication flag requiring mandatory pharmacist verification escalation before label generation — and analyzes how the absence of CBP § 4202 licensure (and by extension the absence of PTCB examination-level training in ISMP high-alert medication protocols) directly caused the dispensing label error; this analysis is organized as PURE KETCHUM advisory material for the CLRA § 1780 fee petition, establishing the professional competency gap between what the PTCB Medications domain required the licensed technician to know and what the unlicensed defendant demonstrably did not know when generating the erroneous "take one tablet daily" label for a once-weekly methotrexate prescription.
• Analyzing the ASHP Standards for Pharmacy Technician Education and Training Programs (PURE KETCHUM) for sterile compounding protocol deviations applicable to the vancomycin IV admixture compounding breach — specifically, the ISO Class 5 primary engineering control requirement and the USP Chapter <797> aseptic technique competency mandates: the attorney reviews the ASHP Standards' sterile compounding competency domain specifications requiring that accredited-program graduates demonstrate mastery of ISO Class 5 PEC use for all compounded sterile preparations; the attorney documents the specific ASHP competency benchmark the unlicensed technician failed to meet — preparation of vancomycin IV admixtures inside an ISO Class 5 LAFW with complete garbing protocol — and analyzes how the absence of ASHP-accredited program training (and the associated CBP § 4202 licensure) directly caused the open-bench compounding that introduced Burkholderia cepacia complex contamination into the vancomycin admixtures; this analysis is organized as PURE KETCHUM advisory material establishing the second private standards advisory in the fee petition, supporting the sterile compounding breach harm track in the CLRA § 1780 lodestar.
• Conducting advisory calls with the patient (or patient representative) on each of the three harm tracks — methotrexate toxicity, Burkholderia cepacia complex bacteremia, and oxycodone diversion — to document the harm narrative and advise on the CLRA § 1780 claim and PTCB/ASHP competency standard deviations: the attorney conducts separate advisory calls addressing: (a) the methotrexate dispensing label error track — reviewing the dispensing label at issue, the prescriber's original prescription, the patient's symptom timeline (onset of pancytopenia, mucositis, and hepatotoxicity), the hospitalization records, and the leucovorin rescue and filgrastim treatment course; (b) the sterile compounding breach track — reviewing the patient's IV therapy records (vancomycin admixture administration dates), the bacteremia workup (blood culture results identifying Burkholderia cepacia complex), the ICU admission records, and the antibiotic therapy course; and (c) the controlled substance diversion track — reviewing the dispensing records, the patient's presentation to the emergency department with uncontrolled post-surgical pain, the wound complication documentation, and any law enforcement or DEA diversion investigation records.

Billing Gap 2 — Expert Coordination: Clinical Pharmacist Expert, Hematologist/Oncologist (Methotrexate Track), Infectious Disease Physician (Compounding Breach Track), and Pain Management Specialist (Diversion Track) (4.00 hrs/yr = $1,200–$2,000)

The second billing gap arises from the active litigation phase — from complaint filing through trial or settlement — during which the attorney coordinates expert consultations, deposition preparation, and trial testimony across the three distinct clinical expert tracks required to litigate the three-track harm in a § 4202 CLRA § 1780 unlicensed pharmacy technician case. Each harm track requires a distinct clinical expert: a clinical pharmacist expert to establish the standard of care for licensed pharmacy technician practice and the PTCB/ASHP competency standards as professional benchmarks; a hematologist/oncologist for the methotrexate toxicity track to document the pancytopenia, mucositis, and hepatotoxicity harm; an infectious disease physician for the compounding breach track to document the Burkholderia cepacia complex bacteremia causation and treatment course; and a pain management specialist for the controlled substance diversion track to document the inadequate post-surgical analgesia harm and wound complications.

• Retaining and coordinating with a clinical pharmacist expert (PharmD, RPh, or board-certified pharmacotherapy specialist BCPS) to establish the standard of care for licensed pharmacy technician practice, document the pharmacist verification checkpoint bypass mechanism, and analyze the PTCB Certification Standards and ASHP Education Standards competency deviations as professional benchmarks in the fee petition: the attorney retains a clinical pharmacist expert — ideally a PharmD with board certification in pharmacotherapy (BCPS) and experience in medication error analysis, USP Chapter <797> sterile compounding practice, and controlled substance management — to provide expert opinions on: (a) the standard of care for California licensed pharmacy technician practice under § 4202 and the CBP regulations, including the pharmacist verification requirement that the unlicensed technician bypassed; (b) the PTCB Medications domain high-alert medication list and LASA drug pair recognition protocols specifically applicable to the methotrexate weekly-dosing flag, and how the absence of PTCB-level competency in the defendant directly caused the dispensing label error; (c) the ASHP Standards' ISO Class 5 PEC requirement for sterile compounding and the specific USP Chapter <797> aseptic technique deviations that allowed Burkholderia cepacia complex contamination of the vancomycin IV admixtures; and (d) the PTCB Federal Requirements domain controlled substance inventory management competency that licensed technicians are required to demonstrate, and how the absence of this competency (through the absence of § 4202 licensing) created the conditions for the oxycodone diversion scheme.
• Coordinating with a hematologist/oncologist expert to document the methotrexate toxicity mechanism, the pancytopenia severity and clinical consequences, the hepatotoxicity and mucositis grades, and the causation link between the weekly-as-daily dispensing label error and the 12-day hospitalization requiring leucovorin rescue and filgrastim G-CSF: the attorney coordinates the hematologist/oncologist expert's deposition preparation and trial testimony on the methotrexate toxicity harm track, covering: the pharmacokinetics of methotrexate dose accumulation over seven days of daily administration of a once-weekly dose (7× cumulative dose accumulation); the clinical manifestations of severe methotrexate toxicity at this accumulation level (pancytopenia with ANC 0.3 and platelets 18K, grade 3 oral mucositis, and transaminase elevation with ALT 485 U/L representing approximately 12× upper limit of normal hepatotoxicity); the treatment course required (leucovorin rescue dosing regimen, filgrastim G-CSF for neutrophil recovery, broad-spectrum antibiotic coverage during the neutropenic nadir, platelet transfusion threshold management, and oral mucositis supportive care); causation analysis establishing the direct chain from the dispensing label error through the daily overdose accumulation to the clinical toxicity syndrome; and the damages calculation including 12-day hospitalization costs, pharmaceutical costs (leucovorin, filgrastim, antibiotics, platelets), and associated professional fees.
• Coordinating with an infectious disease physician expert to document the Burkholderia cepacia complex bacteremia mechanism, the causation link between the open-bench compounding without ISO Class 5 LAFW and the B. cepacia contamination event, and the ICU admission and prolonged antibiotic therapy required for each of the three affected oncology patients: the attorney coordinates the infectious disease physician expert's deposition preparation and trial testimony on the sterile compounding breach harm track, covering: the microbiology of Burkholderia cepacia complex contamination in compounded sterile preparations and the specific environmental contamination sources associated with open-bench (non-ISO 5 PEC) compounding; causation analysis establishing the direct chain from the absence of ISO Class 5 LAFW use through microbial contamination of the vancomycin IV admixtures through the B. cepacia complex bacteremia in the three immunocompromised oncology patients; the clinical course of B. cepacia complex bacteremia in immunocompromised oncology patients (sepsis progression, ICU admission criteria, antimicrobial susceptibility patterns of B. cepacia complex, and the prolonged trimethoprim-sulfamethoxazole and meropenem treatment courses required); and the damages calculation for the leading plaintiff including ICU admission and monitoring costs, extended antibiotic therapy costs (IV meropenem and transition to oral TMP-SMX), and infectious disease specialist professional fees.
• Coordinating with a pain management specialist expert to document the inadequate post-surgical analgesia harm from the oxycodone-for-calcium-carbonate substitution, the emergency department presentations for uncontrolled pain, and the surgical wound complications in the two patients who developed wound healing impairment attributable to inadequate post-operative analgesia and resulting impaired mobility: the attorney coordinates the pain management specialist expert's deposition preparation and trial testimony on the controlled substance diversion harm track, covering: the expected analgesic efficacy of oxycodone-acetaminophen 10/325 for post-operative orthopedic pain management and the complete absence of analgesic effect from calcium carbonate tablets dispensed in its place; the clinical consequences of uncontrolled post-operative pain in orthopedic patients (impaired ambulation, splinting, reduced respiratory effort, impaired wound healing from inadequate mobility); causation analysis for the six emergency department presentations (inadequate analgesia triggering ED visits within 24–48 hours of post-operative discharge when pain was not controlled by the dispensed placebo tablets); the specific wound complication pathology in the two patients who developed surgical wound complications (wound dehiscence, hematoma formation, or surgical site infection attributable to inadequate analgesia-related immobility and compromised wound healing); and the damages calculation for the leading plaintiff including the ED visit costs, wound care costs, and any additional surgical intervention required for wound complications.

Billing Gap 3 — Settlement and Fee Petition: Lodestar Declaration, Ketchum Multiplier, and Missouri v. Jenkins Fees-on-Fees (4.00 hrs/yr = $1,200–$2,000)

The third billing gap arises from the CLRA § 1780 mandatory attorney fee petition — compiling the complete lodestar from the CBP license verification search date (primary Welch anchor) and PTCB CPhT verification date (secondary anchor) through all pre-complaint and litigation tasks through judgment or settlement; briefing the Ketchum multiplier with specific attention to the high-risk, multi-track nature of § 4202 unlicensed pharmacy technician litigation; and establishing the prevailing California market rate under PLCM Group Inc. v. Drexler (22 Cal.4th 1084 (2000)), with all fee petition preparation time recoverable as fees-on-fees under Missouri v. Jenkins (491 U.S. 274 (1989)) through CLRA § 1780.

• Compiling the complete CLRA § 1780 lodestar declaration from the CBP license verification date and PTCB CPhT verification date through all pre-complaint advisory tasks and active litigation tasks through judgment — documenting the dual-anchor narrative (primary CBP BreEZe search and secondary ptcb.org verification), the two private standards analyses (PTCB Certification Standards PURE KETCHUM and ASHP Education Standards PURE KETCHUM), and the four-expert coordination across three harm tracks: the Hensley v. Eckerhart (461 U.S. 424 (1983)) lodestar methodology requires that each billing entry in the fee petition declaration be supported by sufficient contemporaneous time record detail to allow the court to assess the reasonableness of the time expended; in § 4202 unlicensed pharmacy technician cases, each entry should document the specific task (e.g., "CBP BreEZe license verification at search.dca.ca.gov — searched defendant [Name] under license type Pharmacy Technician (TCH) — confirmed no active TCH-prefix license in CBP database as of [date] — screenshot preserved in file — establishes primary Welch anchor and § 4202 per se violation; cross-referenced ptcb.org PTCB CPhT verification under defendant [Name] — confirmed [no PTCB CPhT credential found / PTCB CPhT credential [#] expired as of [date]] — establishes secondary anchor and rules out PTCB certification-based good-faith defense"), the time expended in tenths of an hour, the billing rate, and the relationship of the task to the CLRA § 1780 unlicensed pharmacy technician claim; the lodestar declaration organizes the billing narrative in three task tracks: (i) pre-complaint phase tasks (CBP BreEZe and ptcb.org searches, PTCB Certification Standards high-alert medication deviation analysis [PURE KETCHUM], ASHP Education Standards sterile compounding deviation analysis [PURE KETCHUM], advisory calls for three harm tracks); (ii) active litigation phase tasks (complaint drafting, discovery, four-expert deposition preparation and coordination across three harm tracks, settlement negotiations); and (iii) fee petition phase tasks (lodestar declaration drafting, Ketchum multiplier briefing, PLCM market rate analysis, and response to opposition papers — all recoverable as Missouri v. Jenkins fees-on-fees).
• Ketchum multiplier briefing — establishing the contingency risk of litigating three-track harm across pharmaceutical liability, sterile compounding, and controlled substance diversion, the specialized pharmaceutical knowledge required to prosecute PTCB and ASHP competency deviation claims, and the systemic deterrence value of mandatory CLRA § 1780 fee awards for enforcement of CBP § 4202 pharmacy technician licensing requirements in California dispensing and compounding settings: the Ketchum v. Moses (24 Cal.4th 1122 (2001)) contingency multiplier analysis in § 4202 unlicensed pharmacy technician cases has three distinct components: (a) contingency risk — the plaintiff attorney litigates three parallel harm tracks requiring four distinct clinical experts, each of whom must be retained, prepared, deposed, and potentially taken to trial in proceedings that may last 18–36 months; the defendant pharmacy or pharmacy employer may contest causation on each harm track separately (arguing that the methotrexate toxicity was caused by the patient's own overconsumption, that the Burkholderia cepacia contamination derived from a separate environmental source, and that the opioid diversion was the act of a rogue employee not attributable to the pharmacy employer's negligent supervision); this multi-track causation defense creates substantial litigation risk and contingency exposure for plaintiff counsel; (b) specialized expertise premium — the attorney handling § 4202 unlicensed pharmacy technician claims must develop working familiarity with pharmaceutical dispensing workflow, ISMP high-alert medication list categories, USP Chapter <797> aseptic technique requirements, DEA Schedule II controlled substance inventory management, PTCB examination domain content, and ASHP accreditation program competency standards — a pharmaceutical regulatory knowledge base that commands a significant premium in the California plaintiff bar and that justifies the Ketchum multiplier on the PURE KETCHUM advisory work product; and (c) public interest deterrence — private enforcement of § 4202 through CLRA § 1780 mandatory fee awards protects all California pharmacy patients from the safety risks of unlicensed personnel in the dispensing and compounding workflow, and mandatory fee awards that attract competent plaintiff counsel into this enforcement space provide a private enforcement mechanism for CBP licensing requirements that supplements the CBP's own enforcement capacity.
• PLCM Group hourly rate affidavits and Missouri v. Jenkins fees-on-fees recovery for all fee petition preparation tasks, including the dual-anchor narrative (CBP BreEZe primary and ptcb.org secondary), the two PURE KETCHUM standards analyses (PTCB Certification Standards and ASHP Education Standards), and the four-expert declaration coordination across the three harm tracks: the PLCM Group Inc. v. Drexler (22 Cal.4th 1084 (2000)) market rate analysis for the CLRA § 1780 fee petition requires affidavits from experienced California plaintiff attorneys familiar with the prevailing market rates for the attorney's specific type of work — pharmaceutical consumer fraud, unlicensed health professional practice, and multi-track medication error and compounding breach litigation; the fee petition's market rate documentation should address: (a) prevailing hourly rates for attorneys in the same California market handling CLRA § 1780 pharmaceutical consumer fraud matters of comparable multi-track complexity; (b) the attorney's specific qualifications bearing on the premium rate — pharmaceutical regulatory knowledge base, PTCB and ASHP standards familiarity, USP Chapter <797> aseptic technique competency for cross-examining the sterile compounding expert, and multi-expert coordination experience across pharmaceutical liability, hematology/oncology, infectious disease, and pain management disciplines; and (c) any prior CLRA § 1780 fee awards in comparable pharmaceutical unlicensed practice or medication error consumer fraud matters that confirm the prevailing market rate; under Missouri v. Jenkins (491 U.S. 274 (1989)), all attorney time spent preparing the fee petition itself — CBP BreEZe and ptcb.org dual-anchor narrative, PTCB Certification Standards PURE KETCHUM analysis summary for the fee petition, ASHP Education Standards PURE KETCHUM analysis summary, expert declaration coordination summaries for all four experts, Ketchum multiplier brief, PLCM market rate affidavit, and response to opposition papers — is recoverable as fees-on-fees through CLRA § 1780.

Total Annual Billing Gap — Three-Gap Summary

• Gap 1 (Pre-complaint advisory: CBP license verification, PTCB CPhT verification, ASHP sterile compounding standards deviation analysis, 3 advisory calls for three harm tracks): 5.25 hrs = $1,575–$2,625/yr
• Gap 2 (Expert coordination: clinical pharmacist expert, hematologist/oncologist [methotrexate track], infectious disease physician [compounding breach track], pain management specialist [diversion track]): 4.00 hrs = $1,200–$2,000/yr
• Gap 3 (Settlement and fee petition: lodestar declaration, Ketchum multiplier, Missouri v. Jenkins fees-on-fees): 4.00 hrs = $1,200–$2,000/yr
• Total: 13.25 hrs = $3,975–$6,625/yr untracked at $300–$500/hr median California solo practitioner rate

Frequently Asked Questions

Related California Attorney Fee Petition Pages

• California Board of Pharmacy — Bus. & Prof. Code § 4060 (CBP BreEZe Pharmacist License Verification)
• California Board of Pharmacy — Bus. & Prof. Code § 4324 (Compounding Pharmacy)
• California Medical Board — Bus. & Prof. Code § 2052
• California Board of Registered Nursing — Bus. & Prof. Code § 2878
• California Board of Vocational Nursing — LVN Bus. & Prof. Code § 2878